Claims for Patent: 8,334,374

Summary for Patent: 8,334,374

Title:	Methods and means for obtaining modified phenotypes
Abstract:	Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eukaryotic cells, particularly in plant cells, by providing aberrant, preferably unpolyadenylated, target-specific RNA to the nucleus of the host cell. Preferably, the unpolyadenylated target-specific RNA is provided by transcription of a chimeric gene comprising a promoter, a DNA region encoding the target-specific RNA, a self-splicing ribozyme and a DNA region involved in 3\' end formation and polyadenylation.
Inventor(s):	Waterhouse; Peter Michael (Canberra, AU), Wang; Ming-Bo (Canberra, AU)
Assignee:	Commonwealth Scientific and Industrial Research Organisation (Campbell, AU)
Application Number:	13/474,539
Patent Claims:	1. A chimeric DNA comprising a promoter operably linked to a target specific DNA region which encodes an unpolyadenylated hairpin RNA, wherein the unpolyadenylated hairpin RNA comprises a target specific sense nucleotide sequence and a target specific antisense nucleotide sequence, wherein the target specific antisense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the complement of a part of an RNA molecule transcribed or produced from a nucleic acid of interest in an animal cell, wherein the target specific sense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the part of the RNA molecule transcribed or produced from the nucleic acid of interest, and wherein the target specific sense nucleotide sequence and the target specific antisense nucleotide sequence are complementary to each other so as to form the unpolyadenylated hairpin RNA. 2. The chimeric DNA of claim 1, wherein said target specific sense nucleotide sequence corresponds to a translated region of the nucleic acid of interest. 3. The chimeric DNA of claim 1, wherein the target specific sense nucleotide sequence corresponds to an untranslated region of the RNA produced from the nucleic acid of interest. 4. The chimeric DNA of claim 1, wherein the promoter is recognized by a eukaryotic RNA polymerase I or III and the DNA further comprises a terminator for the polymerase I or III. 5. The chimeric DNA of claim 1, wherein the nucleic acid of interest is a gene incorporated in the genome of the animal cell. 6. The chimeric DNA of claim 1, wherein the nucleic acid of interest is an endogenous gene of the animal cell. 7. The chimeric DNA of claim 1, wherein the nucleic acid of interest is a viral nucleic acid. 8. The chimeric DNA of claim 1, wherein the unpolyadenylated RNA lacks a 5' cap structure. 9. The chimeric DNA of claim 1, wherein the animal cell is a human cell. 10. The chimeric DNA of claim 1, wherein the promoter is a constitutive promoter. 11. The chimeric DNA of claim 1, wherein the promoter is an inducible promoter. 12. The chimeric DNA of claim 1, wherein the promoter is a tissue-specific promoter. 13. The chimeric DNA of claim 1, wherein the promoter is recognized by a single subunit RNA polymerase from a bacteriophage. 14. The chimeric DNA of claim 1, wherein the nucleic acid of interest is a transgene that has been introduced into the animal cell. 15. The chimeric DNA of claim 1, wherein the unpolyadenylated hairpin RNA comprises a sequence from an intron. 16. The chimeric DNA of claim 1, wherein the promoter is recognized by a eukaryotic RNA polymerase III and the DNA further comprises a terminator for the polymerase III. 17. An animal cell in culture comprising a chimeric DNA which comprises a promoter operably linked to a target specific DNA region which encodes an unpolyadenylated hairpin RNA, wherein the unpolyadenylated hairpin RNA comprises a target specific sense nucleotide sequence and a target specific antisense nucleotide sequence, wherein the target specific antisense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the complement of a part of an RNA molecule transcribed or produced from a nucleic acid of interest in the animal cell, wherein the target specific sense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the part of the RNA molecule transcribed or produced from the nucleic acid of interest, and wherein the target specific sense nucleotide sequence and the target specific antisense nucleotide sequence are complementary to each other so as to form the unpolyadenylated hairpin RNA. 18. The animal cell in culture of claim 17, wherein the unpolyadenylated RNA is expressed in the cell. 19. The animal cell in culture of claim 17, which is a human cell in culture.

Details for Patent 8,334,374

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-08-13